# To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)

> **NCT00363545** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1274 (actual)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** Lyophilized formulation of HRV vaccine
- **BIOLOGICAL:** Liquid formulation of HRV vaccine

## Key facts

- **NCT ID:** NCT00363545
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-01
- **Primary completion:** 2007-04-12
- **Final completion:** 2007-04-12
- **Target enrollment:** 1274 (ACTUAL)
- **Last updated:** 2018-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363545, "To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00363545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*